Abstract
Positron emission tomography magnetic resonance imaging (PET/MRI) is an innovative approach that combines the strengths of PET and MRI to enhance the diagnostic accuracy of imaging. MRI creates an intrinsic contrast using the magnetic properties of hydrogen protons, but this intrinsic contrast may not always provide sufficient diagnostic information. To address these shortcomings, MRI contrast agents are used in a complementary and supportive role. Paramagnetic and superparamagnetic MRI contrast agents have different magnetic properties and are preferred for various clinical conditions. The clinical use of contrast agents enables more sensitive diagnostic and personalized treatment approaches based on both anatomical and functional information. Today, hybrid contrast agents developed for PET/MRI systems promise more advanced diagnostic performance compared to other imaging methods, especially in the diagnosis of oncological and cardiovascular diseases, and offer imaging capabilities at the molecular and cellular levels, providing new opportunities in diagnosis and treatment processes.
Keywords: Positron emission tomography, magnetic resonance imaging, contrast media, gadolinium
References
Ibrahim MA, Hazhirkarzar B, Dublin AB. Gadolinium magnetic resonance ımaging. StatPearls. Treasure Island (FL): StatPearls Publishing; 2024.
Frullano L, Meade TJ. Multimodal MRI contrast agents. J Biol Inorg Chem. 2007;12:939-949.
Nevo E, Kamvosoulis P, Currie G. PET/MRI, part 3: protocols and procedures. J Nucl Med Technol. 2022;50:17-24.
Wahsner J, Gale EM, Rodríguez-Rodríguez A, Caravan P. Chemistry of MRI contrast agents: current challenges and new frontiers. Chem Rev. 2019;119:957-1057.
Iyad N, S Ahmad M, Alkhatib SG, Hjouj M. Gadolinium contrast agents- challenges and opportunities of a multidisciplinary approach: Literature review. Eur J Radiol Open. 2023;11:100503.
Strijkers GJ, Mulder WJ, van Tilborg GA, Nicolay K. MRI contrast agents: current status and future perspectives. Anticancer Agents Med Chem. 2007;7:291-305.
Blomqvist L, Nordberg GF, Nurchi VM, Aaseth JO. Gadolinium in medical ımaging-usefulness, toxic reactions and possible countermeasures-a review. biomolecules. 2022;12:742.
Xiao YD, Paudel R, Liu J, Ma C, Zhang ZS, Zhou SK. MRI contrast agents: classification and application (Review). Int J Mol Med. 2016;38:1319-1326.
Maeda H. Vascular permeability in cancer and infection as related to macromolecular drug delivery, with emphasis on the EPR effect for tumor-selective drug targeting. Proc Jpn Acad Ser B Phys Biol Sci. 2012;88:53-71.
Lee MJ, Kim MJ, Yoon CS, Song SY, Park K, Kim WS. The T2-shortening effect of gadolinium and the optimal conditions for maximizing the CNR for evaluating the biliary system: a phantom study. Korean J Radiol. 2011;12:358-364.
McDonald RJ, Weinreb JC, Davenport MS. Symptoms associated with gadolinium exposure (SAGE): a suggested term. Radiology. 2022;302:270-273.
Shokrollahi H. Contrast agents for MRI. Mater Sci Eng C Mater Biol Appl. 2013;33:4485-4497.
Çelik Aydın Ö, Aydın S, Güney H. Kontrast ajanlar; farmakolojik özellikleri, genel advers reaksiyonları ve ilaç etkileşimleri. Ankara Eğitim ve Araştırma Hastanesi Tıp Dergisi. 2020;53:61–67.
Idée JM, Port M, Robic C, Medina C, Sabatou M, Corot C. Role of thermodynamic and kinetic parameters in gadolinium chelate stability. J Magn Reson Imaging. 2009;30:1249-1258.
Pan D, Schmieder AH, Wickline SA, Lanza GM. Manganese-based MRI contrast agents: past, present and future. Tetrahedron. 2011;67:8431-8444.
Shim SY, Lim DK, Nam JM. Ultrasensitive optical biodiagnostic methods using metallic nanoparticles. Nanomedicine (Lond). 2008;3:215-232.
Oberdick SD, Jordanova KV, Lundstrom JT, et al. Iron oxide nanoparticles as positive T1 contrast agents for low-field magnetic resonance imaging at 64 mT. Sci Rep. 2023;13:11520.
Wang YX. Superparamagnetic iron oxide based MRI contrast agents: Current status of clinical application. Quant Imaging Med Surg. 2011;1:35-40.
Rahman M. Magnetic resonance ımaging and ıron-oxide nanoparticles in the era of personalized medicine. Nanotheranostics. 2023;7:424-449.
Runge VM, Schoerner W, Niendorf HP, et al. Initial clinical evaluation of gadolinium DTPA for contrast-enhanced magnetic resonance imaging. Magn Reson Imaging. 1985;3:27-35.
Dokumacı DŞ. Manyetik rezonans görüntüleme kontrast maddeleri ve yan etkileri. Harran Üniversitesi Tıp Fakültesi Dergisi. 2012;9:119–125.
Verloh N, Utpatel K, Haimerl M, et al. Liver fibrosis and Gd-EOB-DTPA-enhanced MRI: A histopathologic correlation. Sci Rep. 2015;5:15408.
Nolte-Ernsting C, Adam G, Bücker A, Berges S, Bjørnerud A, Günther RW. Abdominal MR angiography performed using blood pool contrast agents: comparison of a new superparamagnetic iron oxide nanoparticle and a linear gadolinium polymer. AJR Am J Roentgenol. 1998;171:107-113.
Reimer P, Schneider G, Schima W. Hepatobiliary contrast agents for contrast-enhanced MRI of the liver: properties, clinical development and applications. Eur Radiol. 2004;14:559-578.
Runge VM. A comparison of two MR hepatobiliary gadolinium chelates: Gd-BOPTA and Gd-EOB-DTPA. J Comput Assist Tomogr. 1998;22:643-650.
Mohabir S, Pitcher RD, Perumal R, Goodier MDM. The efficacy of pineapple juice as a negative oral contrast agent in magnetic resonance cholangiopancreatography. SA J Radiol. 2020;24:1875.
Bulte JW, Kraitchman DL. Iron oxide MR contrast agents for molecular and cellular imaging. NMR Biomed. 2004;17:484-499.
Kiani A, Esquevin A, Lepareur N, Bourguet P, Le Jeune F, Gauvrit J. Main applications of hybrid PET-MRI contrast agents: a review. Contrast Media Mol Imaging. 2016;11:92-98.
Jennings LE, Long NJ. 'Two is better than one'--probes for dual-modality molecular imaging. Chem Commun (Camb). 2009;3511-3524.
Yankeelov TE, Peterson TE, Abramson RG, et al. Simultaneous PET-MRI in oncology: a solution looking for a problem? Magn Reson Imaging. 2012;30:1342-1356.
Frullano L, Catana C, Benner T, Sherry AD, Caravan P. Bimodal MR-PET agent for quantitative pH imaging. Angew Chem Int Ed Engl. 2010;49:2382-2384.
Brismar TB, Grishenkov D, Gustafsson B, et al. Magnetite nanoparticles can be coupled to microbubbles to support multimodal imaging. Biomacromolecules. 2012;13:1390-1399.
Glaus C, Rossin R, Welch MJ, Bao G. In vivo evaluation of (64)Cu-labeled magnetic nanoparticles as a dual-modality PET/MR imaging agent. Bioconjug Chem. 2010;21:715-722.
Choi J, Park JC, Nah H, et al. A hybrid nanoparticle probe for dual-modality positron emission tomography and magnetic resonance imaging. Angew Chem Int Ed Engl. 2008;47:6259-6262.
Lee HY, Li Z, Chen K, et al. PET/MRI dual-modality tumor imaging using arginine-glycine-aspartic (RGD)-conjugated radiolabeled iron oxide nanoparticles. J Nucl Med. 2008;49:1371-1379.
Li S, Goins B, Zhang L, Bao A. Novel multifunctional theranostic liposome drug delivery system: construction, characterization, and multimodality MR, near-infrared fluorescent, and nuclear imaging. Bioconjug Chem. 2012;23:1322-1332.
Zhou Z, Lu ZR. Gadolinium-based contrast agents for magnetic resonance cancer imaging. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2013;5:1-18.
Weinreb JC, Rodby RA, Yee J, et al. Use of intravenous gadolinium-based contrast media in patients with kidney disease: consensus statements from the American College of Radiology and the National Kidney Foundation. Radiology. 2021;298:28-35.
Shahid I, Joseph A, Lancelot E. Use of real-life safety data from international pharmacovigilance databases to assess the importance of symptoms associated with gadolinium exposure. Invest Radiol. 2022;57:664-673.
Ramalho J, Semelka RC, Ramalho M, Nunes RH, AlObaidy M, Castillo M. Gadolinium-based contrast agent accumulation and toxicity: an update. AJNR Am J Neuroradiol. 2016;37:1192-1198.
Lois C, Bezrukov I, Schmidt H, et al. Effect of MR contrast agents on quantitative accuracy of PET in combined whole-body PET/MR imaging. Eur J Nucl Med Mol Imaging. 2012;39:1756-1766.
